Post-restructuring, Biogen’s top execs are back in the R&D talent hunt

John Carroll SAN FRANCISCO–Four months after Biogen swiftly slashed 880 jobs in a wrenching restructuring, the biotech trendsetter is back on a new hiring spree in research aimed ...

With predators knocking, Shire needs to go on the hunt, analysts say

Carly Helfand They say the best defense is a good offense, and that just may be the case for Shire. Amid pharma's ongoing deal frenzy, the Dublin-based company–a prime target ...

As germs outpace antibiotics, developers hunt for new solutions

Damian Garde The rise of antibiotic-resistant bacteria has become a global scourge, and researchers across academia and industry are taking novel steps to fight back. FierceBiotech ...

Public Citizen goes on a witch hunt at the FDA

John Carroll FierceBiotech has covered its share of stories on money scandals and drug development, but this is a tempest in a proverbial tea pot. FierceBiotech News

With NIH support, Eli Lilly follows NPS Pharma into hunt for rare-disease therapy

Ryan McBride Eli Lilly has found a new path into the hot rare-disease field. An NIH program has backed the Indianapolis-based drug giant's preclinical-stage research of a potential ...

Onyx CEO dismisses rumors that Amgen alone is still in the hunt

Eric Palmer Amgen reportedly raised its bid for Onyx Pharmaceuticals this week 10 bucks a share to $ 130, valuing the company at $ 9.5 billion and driving out other interested ...

GlaxoSmithKline forges ahead with hunt for Chinese vaccine partners

Tracy Staton GlaxoSmithKline may be suffering through a corruption scandal in China, but that hasn't interfered with its plans to team up with a Chinese company on vaccines. Its ...

Hunt for 2013 Fierce 15 begins… Release the biotech hounds!

Ryan McBride Calling everyone from the global biotech community. We've begun seeking nominations for FierceBiotech's 2013 class of Fierce 15 companies, and our editors would ...

Merck marks another failure in elusive hunt for Parkinson’s disease drugs

Ryan McBride Merck has cut one of most advanced efforts to develop a new therapy for Parkinson's disease. Its Phase III clinical trials of preladenant for the prevalent neurological ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS